Vanguard Group Inc. raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,007,935 shares of the biopharmaceutical company’s stock after purchasing an additional 15,600 shares during the quarter. Vanguard Group Inc. owned approximately 3.63% of Catalyst Pharmaceuticals worth $5,865,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Knott David M acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $554,000. JPMorgan Chase & Co. acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $155,000. Bank of New York Mellon Corp lifted its position in shares of Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the last quarter. Finally, Oxford Asset Management lifted its position in shares of Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.
Several analysts recently weighed in on the company. Zacks Investment Research cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $5.00 price target on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $4.90.
Catalyst Pharmaceuticals, Inc. (NASDAQ CPRX) opened at 2.44 on Friday. The company’s market cap is $206.31 million. The firm’s 50-day moving average price is $2.70 and its 200-day moving average price is $2.29. Catalyst Pharmaceuticals, Inc. has a 1-year low of $0.94 and a 1-year high of $3.20.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post ($0.23) EPS for the current fiscal year.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, with a total value of $51,600.00. Following the transaction, the insider now directly owns 4,471,026 shares in the company, valued at approximately $11,535,247.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 8.79% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.